Hangzhou, Zhejiang, China, October 9, 2026 — Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics"), a clinical-stage biopharmaceutical company and a controlled subsidiary of Huadong Medicine Co., Ltd., focused on developing innovative biologic therapeutics for metabolic diseases and cancer, today announced that the first patient has been dosed in the Phase II clinical study of its independently developed first-in-class (FIC) long-acting trispecific agonist DR10624 targeting fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon-like peptide-1 receptor (GLP-1R), for the treatment of moderate hypertriglyceridemia complicated with diabetic kidney disease (moderate HTG with DKD) (the "DR10624-204 study").
The DR10624-204 study is a multicenter, randomized, double-blind, placebo-controlled parallel-group clinical study designed to evaluate the efficacy, safety, immunogenicity, and PK characteristics of DR10624 in trial participants with moderate HTG complicated with DKD. The lead site and principal investigators for this project are Professor Tang Yida of Peking University Third Hospital and Professor Zhao Minghui of Peking University First Hospital, respectively. The site that dosed the first patient in this study was Nanjing First Hospital (investigator: Director Li Qian).
Dr. Huang Yanshan, Founder and Chief Executive Officer of Doer Biologics, commented, "DR10624 is a first-in-class long-acting three-target agonist targeting FGF21R, GCGR, and GLP-1R, developed using Doer Biologics' proprietary MultipleBody® platform technology, designed to exhibit balanced activity against metabolic diseases. In non-clinical and clinical studies, it has demonstrated extraordinary efficacy in lowering triglycerides, normalizing blood lipids, and improving liver function."
Dr. Fang Yongliang, Chief Operating Officer of Doer Biologics, stated, "We are pleased to announce that the DR10624-204 study has successfully completed enrollment of the first subject. Patients with diabetic kidney disease often have concomitant hypertriglyceridemia. Triglycerides accelerate the deterioration of kidney function through lipotoxicity, while impaired kidneys further aggravate lipid metabolism disorders. The combined effect of both significantly accelerates the progression of renal failure and substantially increases the risk of death from cardiovascular diseases (such as myocardial infarction and stroke). The previously completed DR10624-201 study preliminarily suggested that DR10624, while lowering triglycerides, can also improve important renal indicators, suggesting that DR10624 may improve metabolism and renal function in patients with diabetic kidney disease. We look forward to completing enrollment of all subjects in this study as soon as possible."
For more information about the DR10624-204 study, please visit the Drug Clinical Trial Registration and Information Disclosure Platform (registration number: CTR20262589).